The global pneumonia testing market size was estimated to be USD 0.65743 Billion in 2023 and is expected to reach at USD 1.4198 Billion by 2033 with a CAGR of 7.25% during the forecast period 2023-2033. Growing adoption of point of care (POC) testing, rising development in the field of nucleic acid detection, increasing advancements in pneumonia diagnostics, surge in prevalence of pneumonia among children, growing healthcare expenditure, rising favourable reimbursement policies, and increasing approvals of point-of-care molecular diagnostics for early detection of pneumonia are some of the key factors boosting the market growth.
Increasing approvals of point-of-care molecular diagnostics for early detection of pneumonia is predicted to boost the market growth during the forecast period. For instance, in March 2020, SSI Diagnostica A/S has been granted approval by the U.S. FDA for their ImmuView S pneumoniae and L pneumophila Urinary Antigen Test. This rapid lateral flow test is designed for the detection of Streptococcus pneumoniae and Legionella pneumophila antigens in urine samples.
By Type, Analyzers was the highest revenue-grossing segment in the global pneumonia testing market in 2022 owing to rising demand & usage for pneumonia tests, growing technological advancements, and increasing demand for advanced devices, and increasing launch of new products. Additionally, Consumables is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities, rising usage of these products for various testing procedures, surge in demand for microbial testing, and increasing acquisition within market players. For instance, in February 2021, Mesa Biotech, Inc., a privately held molecular diagnostic firm focusing in point-of-care solutions, has been successfully acquired by Thermo Fisher Scientific Inc., as previously stated.
By Product, Streptococcus-based was the highest revenue-grossing segment in the global pneumonia testing market in 2022 owing to increasing prevalence of Community-acquired Pneumonia, growing demand for bacterial-infection diagnosis testing and rising technological developments. Additionally, Mycoplasma Pneumonia-based is predicted to grow at fastest CAGR during the forecast period owing to the rising number of mycoplasma pneumonia cases, surge in number of hospitalizations, and increasing demand for diagnostics tests. For instance, in July 2020, bioMerieux SA introduced BIOFIRE MYCOPLASMA, an advanced test designed to detect mycoplasma in biotherapeutic pharmaceutical products, including antibodies, hormones, cell therapies, and gene therapies.
By Method, Point-of-care (POC) testing was the highest revenue-grossing segment in the global Pneumonia Testing Market in 2022 owing to increasing prevalence of pneumonia, growing geriatric population, rising adoption of sedentary lifestyles & unhealthy food habits, surge in demand for POC testing, and increasing product approvals. For instance, in July 2023, Lumos Diagnostics has been granted approval by the US Food and Drug Administration (FDA) to market its FebriDx® rapid, point-of-care test in the United States, as per the company's announcement. Additionally, Molecular diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of chronic diseases, increasing demand for diagnostic testing, rising technological advancements, and growing launch of new products.
By Technology, Enzyme-linked immunosorbent assay was the highest revenue-grossing segment in the global Pneumonia Testing Market in 2022 owing to surge in demand for advanced diagnostic techniques and growing number of contract research organizations (CROs). Additionally, Polymerase chain reaction is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of chronic & infectious diseases, growing demand for point-of-care tests & self-tests, rising technological advancements in PCR testing, surge in demand for polymerase chain reaction tests, increasing launch of novel technologies. For instance, in September 2021, CerTest Biotec has created and successfully validated its CE-IVD multiplex assay called VIASURE C. pneumoniae, M. pneumoniae & L. pneumophila real-time PCR kit. This kit is designed for the detection of the main pathogens associated with atypical pneumoniae.
By End-user, Hospitals was the highest revenue-grossing segment in the global Pneumonia Testing Market in 2022 owing to rising number of patients suffering from pneumonia, increasing demand for diagnostic tests, and surge in favourable reimbursement policies. Additionally, Diagnostic laboratories is predicted to grow at fastest CAGR during the forecast period owing to the surge in diagnostic procedures, growing number of diagnostic centres, increasing adoption of pneumonia diagnostic testing, and rising partnership within market players. For instance, in May 2022, B·R·A·H·M·S GmbH, a partner of Thermo Fisher Scientific, has collaborated with DiaSorin S.p.A to jointly develop and bring to market the innovative LIAISON B.R.A.H.M.S MR-proADM immunodiagnostic test. This assay aims to assist in the diagnosis of various conditions, including sepsis, septic shock, lower tract respiratory infections, urinary tract infections, and kidney disease.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing healthcare infrastructure, growing prevalence of chronic diseases, rising healthcare expenditure, presence of major market players, surge in awareness regarding the disease, increasing product approval, and growing collaborations within market players. For instance, in February 2022, Cue Health Inc and Cardinal Health have decided to prolong their distribution agreement for Cue's COVID-19 tests, enabling utilization for both professional and over-the-counter purposes. This collaboration is significant as Cardinal Health's extensive network covers nearly 90% of LIS hospitals and over 60,000 pharmacies, thereby expanding the accessibility and acceptance of Cue's innovative nucleic acid amplification test (NAAT) in various healthcare settings. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of pneumonia, growing geriatric population, increasing awareness regarding diagnostic testing, and surge in launch of new products. For instance, in October 2021, Fujifilm India and Bangalore-based multi-speciality private healthcare provider Sakra World Hospital have joined forces to introduce an AI-enabled software that supports doctors in diagnosing COVID-19 pneumonia.
Increasing approvals of point-of-care molecular diagnostics for early detection of pneumonia is predicted to boost the market growth during the forecast period. For instance, in March 2020, SSI Diagnostica A/S has been granted approval by the U.S. FDA for their ImmuView S pneumoniae and L pneumophila Urinary Antigen Test. This rapid lateral flow test is designed for the detection of Streptococcus pneumoniae and Legionella pneumophila antigens in urine samples.
By Type, Analyzers was the highest revenue-grossing segment in the global pneumonia testing market in 2022 owing to rising demand & usage for pneumonia tests, growing technological advancements, and increasing demand for advanced devices, and increasing launch of new products. Additionally, Consumables is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities, rising usage of these products for various testing procedures, surge in demand for microbial testing, and increasing acquisition within market players. For instance, in February 2021, Mesa Biotech, Inc., a privately held molecular diagnostic firm focusing in point-of-care solutions, has been successfully acquired by Thermo Fisher Scientific Inc., as previously stated.
By Product, Streptococcus-based was the highest revenue-grossing segment in the global pneumonia testing market in 2022 owing to increasing prevalence of Community-acquired Pneumonia, growing demand for bacterial-infection diagnosis testing and rising technological developments. Additionally, Mycoplasma Pneumonia-based is predicted to grow at fastest CAGR during the forecast period owing to the rising number of mycoplasma pneumonia cases, surge in number of hospitalizations, and increasing demand for diagnostics tests. For instance, in July 2020, bioMerieux SA introduced BIOFIRE MYCOPLASMA, an advanced test designed to detect mycoplasma in biotherapeutic pharmaceutical products, including antibodies, hormones, cell therapies, and gene therapies.
By Method, Point-of-care (POC) testing was the highest revenue-grossing segment in the global Pneumonia Testing Market in 2022 owing to increasing prevalence of pneumonia, growing geriatric population, rising adoption of sedentary lifestyles & unhealthy food habits, surge in demand for POC testing, and increasing product approvals. For instance, in July 2023, Lumos Diagnostics has been granted approval by the US Food and Drug Administration (FDA) to market its FebriDx® rapid, point-of-care test in the United States, as per the company's announcement. Additionally, Molecular diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of chronic diseases, increasing demand for diagnostic testing, rising technological advancements, and growing launch of new products.
By Technology, Enzyme-linked immunosorbent assay was the highest revenue-grossing segment in the global Pneumonia Testing Market in 2022 owing to surge in demand for advanced diagnostic techniques and growing number of contract research organizations (CROs). Additionally, Polymerase chain reaction is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of chronic & infectious diseases, growing demand for point-of-care tests & self-tests, rising technological advancements in PCR testing, surge in demand for polymerase chain reaction tests, increasing launch of novel technologies. For instance, in September 2021, CerTest Biotec has created and successfully validated its CE-IVD multiplex assay called VIASURE C. pneumoniae, M. pneumoniae & L. pneumophila real-time PCR kit. This kit is designed for the detection of the main pathogens associated with atypical pneumoniae.
By End-user, Hospitals was the highest revenue-grossing segment in the global Pneumonia Testing Market in 2022 owing to rising number of patients suffering from pneumonia, increasing demand for diagnostic tests, and surge in favourable reimbursement policies. Additionally, Diagnostic laboratories is predicted to grow at fastest CAGR during the forecast period owing to the surge in diagnostic procedures, growing number of diagnostic centres, increasing adoption of pneumonia diagnostic testing, and rising partnership within market players. For instance, in May 2022, B·R·A·H·M·S GmbH, a partner of Thermo Fisher Scientific, has collaborated with DiaSorin S.p.A to jointly develop and bring to market the innovative LIAISON B.R.A.H.M.S MR-proADM immunodiagnostic test. This assay aims to assist in the diagnosis of various conditions, including sepsis, septic shock, lower tract respiratory infections, urinary tract infections, and kidney disease.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing healthcare infrastructure, growing prevalence of chronic diseases, rising healthcare expenditure, presence of major market players, surge in awareness regarding the disease, increasing product approval, and growing collaborations within market players. For instance, in February 2022, Cue Health Inc and Cardinal Health have decided to prolong their distribution agreement for Cue's COVID-19 tests, enabling utilization for both professional and over-the-counter purposes. This collaboration is significant as Cardinal Health's extensive network covers nearly 90% of LIS hospitals and over 60,000 pharmacies, thereby expanding the accessibility and acceptance of Cue's innovative nucleic acid amplification test (NAAT) in various healthcare settings. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of pneumonia, growing geriatric population, increasing awareness regarding diagnostic testing, and surge in launch of new products. For instance, in October 2021, Fujifilm India and Bangalore-based multi-speciality private healthcare provider Sakra World Hospital have joined forces to introduce an AI-enabled software that supports doctors in diagnosing COVID-19 pneumonia.
Segmentation: Pneumonia Testing Market Report 2022 - 2033
Pneumonia Testing Market Analysis & Forecast by Type 2022 - 2033 (Revenue USD Mn)
- Consumables
- Analyzers
Pneumonia Testing Market Analysis & Forecast by Product 2022 - 2033 (Revenue USD Mn)
- Mycoplasma Pneumonia-based
- Legionella-based
- Streptococcus-based
- Viral Pneumonia-based
- Chlamydophilla-based
Pneumonia Testing Market Analysis & Forecast by Method 2022 - 2033 (Revenue USD Mn)
- Immunodiagnostics
- Molecular Diagnostics
- Point-of-Care Testing
Pneumonia Testing Market Analysis & Forecast by Technology 2022 - 2033 (Revenue USD Mn)
- Immunofluoroscence
- Western Blot
- Enzyme Linked Immunosorbant Assay
- Polymerase Chain Reaction
- Imunohistochemistry
- Others
Pneumonia Testing Market Analysis & Forecast by End-user 2022 - 2033 (Revenue USD Mn)
- Diagnostic Laboratories
- Homecare
- Hospitals
- Others
Pneumonia Testing Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Mn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Pneumonia Testing Market: Type Estimates & Trend Analysis
8. Pneumonia Testing Market: Product Estimates & Trend Analysis
9. Pneumonia Testing Market: Method Estimates & Trend Analysis
10. Pneumonia Testing Market: Technology Estimates & Trend Analysis
11. Pneumonia Testing Market: End-user Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Pneumonia Testing Market
14. Europe Global Pneumonia Testing Market
15. Asia Pacific Global Pneumonia Testing Market
16. Latin America Global Pneumonia Testing Market
17. MEA Global Pneumonia Testing Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- F-Hoffmann la Roche Ltd.
- Quidel
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Bio-Rad Laboratories Inc.
- Hologic Inc.
- Becton
- Dickenson and Company
- BioMerieux
- Quest Diagnostics
- Meridian Biosciences
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 0.66 Billion |
| Forecasted Market Value ( USD | $ 1.42 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
